Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Hong Kong man jailed 21 months for throwing eggsCalifornia doctor with cancer gets rare lungKaimanawa horses adoptions threatened by cost of livingUS warns China will use Olympics to gloss over abusesNew Zealand joins 50 countries in condemning transfer of weapons between North Korea and RussiaBlizzard strikes North America, cancelling flights and disrupting presidential campaignAuckland bus services disrupted by police search warrantChinese company says coronavirus vaccine ready by early 2021Iran sentences Nobel laureate Narges Mohammadi to additional prison termIsrael reined in by International Court of Justice rulings on Gaza